Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

J. Biol. Chem. 277 (44): 42034-42048

© 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

Mutations in the Extracellular Amino-terminal Domain of the NK2 Neurokinin Receptor Abolish cAMP Signaling but Preserve Intracellular Calcium Responses*

Sandra LecatDagger §, Bernard Bucher, Yves Mely, and Jean-Luc GalziDagger ||

From Dagger  CNRS UPR9050, Récepteurs et Protéines Membranaires, Ecole Supérieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brandt, Illkirch 67400, France and  CNRS UMR7034 Pharmacologie et Physicochimie des Interactions Cellulaires et Moléculaires, Université Louis Pasteur de Strasbourg, Faculté de Pharmacie 74, Route du Rhin, Illkirch BP 24 67401, France

By combining real time measurements of agonist binding, by fluorescence resonance energy transfer, and of subsequent responses, we proposed previously that the neurokinin NK2 receptor preexists in equilibrium between three states: inactive, calcium-triggering, and cAMP-producing. Thr24 and Phe26 of the NK2 receptor extracellular domain are considered to interact with neuropeptide agonists based on the reduction of affinity when they are substituted by alanine. Using fluorescence resonance energy transfer, we now quantify the binding kinetics of two Texas Red-modified neurokinin A agonists to the fluorescent wild-type (Y-NK2wt) and the mutant (Y-NK2mut) receptor carrying Thr24 right-arrow Ala and Phe26 right-arrow Ala mutations. TR1-neurokinin A binds with a fast component and a slow component to the Y-NK2wt receptor and triggers both a calcium and a cAMP response. In contrast, on the mutant receptor, it binds in a single fast step with a lower apparent affinity and activates only the calcium response. Another agonist, TRC4-neurokinin A, binds to both wild-type and mutant receptors in a single fast step, with similar affinities and kinetics and promotes only calcium signaling. Kinetic modeling of ligand binding and receptor interconversions is carried out to analyze phenotypic changes in terms of binding alterations or changes in the transitions between conformational states. We show that the binding and response properties of the Y-NK2mut receptor are best described according to a phenotype where a reduction of the transition between the inactive and the active states occurs.

* This work was supported by CNRS and the Association pour la Recherche sur le Cancer (ARC).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of an ARC fellowship.

|| To whom correspondence should be addressed. Tel.: 33-3-90-24-47-59; Fax: 33-3-90-24-48-29; E-mail:

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

Pirenzepine Promotes the Dimerization of Muscarinic M1 Receptors through a Three-step Binding Process.
B. Ilien, N. Glasser, J.-P. Clamme, P. Didier, E. Piemont, R. Chinnappan, S. B. Daval, J.-L. Galzi, and Y. Mely (2009)
J. Biol. Chem. 284, 19533-19543
   Abstract »    Full Text »    PDF »
Organic Anion Transporter OAT1 Undergoes Constitutive and Protein Kinase C-regulated Trafficking through a Dynamin- and Clathrin-dependent Pathway.
Q. Zhang, M. Hong, P. Duan, Z. Pan, J. Ma, and G. You (2008)
J. Biol. Chem. 283, 32570-32579
   Abstract »    Full Text »    PDF »
Post-activation-mediated Changes in Opioid Receptors Detected by N-terminal Antibodies.
A. Gupta, R. Rozenfeld, I. Gomes, K. M. Raehal, F. M. Decaillot, L. M. Bohn, and L. A. Devi (2008)
J. Biol. Chem. 283, 10735-10744
   Abstract »    Full Text »    PDF »
Changes in angiotensin II type 1 receptor signalling pathways evoked by a monoclonal antibody raised to the N-terminus.
F. Xiao, J. R Puddefoot, S. Barker, and G. P Vinson (2008)
J. Endocrinol. 197, 25-33
   Abstract »    Full Text »    PDF »
Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor.
M A Redondo-Muller, M Stevanovic-Walker, S Barker, J R Puddefoot, and G P Vinson (2008)
Endocr. Relat. Cancer 15, 277-288
   Abstract »    Full Text »    PDF »
A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties.
E. L. Maillet, N. Pellegrini, C. Valant, B. Bucher, M. Hibert, J.-J. Bourguignon, and J.-L. Galzi (2007)
FASEB J 21, 2124-2134
   Abstract »    Full Text »    PDF »
Conformation State-sensitive Antibodies to G-protein-coupled Receptors.
A. Gupta, F. M. Decaillot, I. Gomes, O. Tkalych, A. S. Heimann, E. S. Ferro, and L. A. Devi (2007)
J. Biol. Chem. 282, 5116-5124
   Abstract »    Full Text »    PDF »
Dynamic Confinement of NK2 Receptors in the Plasma Membrane: IMPROVED FRAP ANALYSIS AND BIOLOGICAL RELEVANCE.
L. Cezanne, S. Lecat, B. Lagane, C. Millot, J.-Y. Vollmer, H. Matthes, J.-L. Galzi, and A. Lopez (2004)
J. Biol. Chem. 279, 45057-45067
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882